Cue Biopharma Inc (CUE)
1.02
-0.01
(-0.97%)
USD |
NASDAQ |
Nov 22, 16:00
1.05
+0.03
(+2.94%)
After-Hours: 20:00
Cue Biopharma Revenue (TTM): 9.532M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 9.532M |
| June 30, 2024 | 8.296M |
| March 31, 2024 | 7.02M |
| December 31, 2023 | 5.49M |
| September 30, 2023 | 3.82M |
| June 30, 2023 | 1.788M |
| March 31, 2023 | 0.432M |
| December 31, 2022 | 1.245M |
| September 30, 2022 | 9.348M |
| June 30, 2022 | 11.68M |
| March 31, 2022 | 14.39M |
| December 31, 2021 | 14.94M |
| Date | Value |
|---|---|
| September 30, 2021 | 7.162M |
| June 30, 2021 | 5.471M |
| March 31, 2021 | 3.807M |
| December 31, 2020 | 3.154M |
| September 30, 2020 | 3.728M |
| June 30, 2020 | 4.008M |
| March 31, 2020 | 3.988M |
| December 31, 2019 | 3.458M |
| September 30, 2019 | 2.740M |
| June 30, 2019 | 2.205M |
| March 31, 2019 | 1.322M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
0.432M
Minimum
Mar 2023
14.94M
Maximum
Dec 2021
6.138M
Average
4.740M
Median
Revenue (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 2.753B |
| Arbutus Biopharma Corp | 6.742M |
| GlycoMimetics Inc | -- |
| FibroGen Inc | 180.01M |
| Cidara Therapeutics Inc | -- |